AngioDynamics (ANGO) Competitors

Integra LifeSciences (NASDAQ:IART) and AngioDynamics (NASDAQ:ANGO) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, community ranking, institutional ownership, valuation, risk, analyst recommendations and earnings.

Does the MarketBeat Community prefer IART or ANGO?

Integra LifeSciences received 68 more outperform votes than AngioDynamics when rated by MarketBeat users. However, 61.26% of users gave AngioDynamics an outperform vote while only 56.81% of users gave Integra LifeSciences an outperform vote.

Company	Underperform	Outperform
Integra LifeSciences	Outperform Votes 438 56.81%	Underperform Votes 333 43.19%
AngioDynamics	Outperform Votes 370 61.26%	Underperform Votes 234 38.74%

Which has more risk and volatility, IART or ANGO?

Integra LifeSciences has a beta of 1.24, meaning that its stock price is 24% more volatile than the S&P 500. Comparatively, AngioDynamics has a beta of 0.52, meaning that its stock price is 48% less volatile than the S&P 500.

Which has better valuation & earnings, IART or ANGO?

Integra LifeSciences has higher revenue and earnings than AngioDynamics. Integra LifeSciences is trading at a lower price-to-earnings ratio than AngioDynamics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Integra LifeSciences	$1.61B	0.79	$67.74M	-$0.09	-182.67
AngioDynamics	$283.32M	1.32	-$184.35M	-$1.01	-9.10

Do institutionals and insiders believe in IART or ANGO?

84.8% of Integra LifeSciences shares are owned by institutional investors. Comparatively, 89.4% of AngioDynamics shares are owned by institutional investors. 3.5% of Integra LifeSciences shares are owned by insiders. Comparatively, 5.4% of AngioDynamics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Does the media refer more to IART or ANGO?

In the previous week, Integra LifeSciences had 2 more articles in the media than AngioDynamics. MarketBeat recorded 9 mentions for Integra LifeSciences and 7 mentions for AngioDynamics. AngioDynamics' average media sentiment score of 1.14 beat Integra LifeSciences' score of 0.96 indicating that AngioDynamics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Integra LifeSciences	4 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
AngioDynamics	1 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is IART or ANGO more profitable?

Integra LifeSciences has a net margin of -0.42% compared to AngioDynamics' net margin of -79.38%. Integra LifeSciences' return on equity of 12.35% beat AngioDynamics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Integra LifeSciences	-0.42%	12.35%	4.82%
AngioDynamics	-79.38%	-7.26%	-4.78%

Do analysts rate IART or ANGO?

Integra LifeSciences currently has a consensus price target of $22.71, indicating a potential upside of 38.16%. AngioDynamics has a consensus price target of $14.00, indicating a potential upside of 52.34%. Given AngioDynamics' stronger consensus rating and higher probable upside, analysts clearly believe AngioDynamics is more favorable than Integra LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Integra LifeSciences	3 Sell rating(s)	4 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.89
AngioDynamics	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Summary

Integra LifeSciences beats AngioDynamics on 9 of the 17 factors compared between the two stocks.